Prognostic factors related to recurrent endometrial carcinoma following initial surgery

Norbert Vavra1a, Ursula Denison1, Herwig Kucera1, Monir Barrada1, Christine Kurz1, Heinz Salzer1 and Paul Sevelda1

1 First Department of Gynecology and Obstetrics, University of Vienna, Spitalgasse 23, A-1090, Vienna, Austria
a Correspondence: Norbert Vavra, First Department of Gynecology and Obstetrics University of Vienna Spitalgasse 23, A-1090, Vienna, Austria


Site of recurrence and histological type are significant prognostic factors for survival in recurrent endometrial carcinoma.
The aim of this retrospective analysis of 56 patients suffering from recurrences of endometrial carcinoma following initial surgery was to establish the prognostic relevance that the following factors had on the survival rate: age, primary tumor stage, histological assessment (papillary vs non-papillary), postoperative adjuvant radiation therapy, recurrence free interval (<24 months, >24 months) and localisation of recurrence. The univariate analysis showed a significantly longer median survival time after recurrence for the following parameters: local recurrence vs extra vaginal recurrence (77.5 months vs 15.7 months, p=0.02), non-papillary vs papillary carcinoma (36.1 months vs 7.7 months, p=0.02), no adjuvant irradiation vs adjuvant irradiation (82.0 months vs 8.8 months, p = 0.007). Patients after adjuvant radiation treatment and patients suffering from papillary carcinomas have a significantly higher proportion of patients with distant metastasis (patients with adjuvant radiation treatment: Chi-square test: p = 0.001; patients suffering from papillary carcinomas: p=0.033).
In the case of local recurrences, a three year survival rate of 54% can be achieved with radiation treatment. Recurrences of papillary endometrial carcinomas and patients suffering from distant metastasis on the other hand, show very low survival rates if they are treated with radiation therapy (papillary carcinomas: three-year survival rate of 18%, patients suffering from distant metastasis: 19%). These patients should be included in randomised studies with a view to examining the therapeutic effects of either additional or exclusive treatment with chemotherapy.

Menü schließen